Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy

Takashi Kawahara, Sachi Fukui, Kentaro Sakamaki, Yusuke Ito, Hiroki Ito, Naohito Kobayashi, Koji Izumi, Yumiko Yokomizo, Yasuhide Miyoshi, Kazuhide Makiyama, Noboru Nakaigawa, Takeharu Yamanaka, Masahiro Yao, Hiroshi Miyamoto, Hiroji Uemura

Research output: Contribution to journalArticle

Abstract

Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has been demonstrated as an independent prognosticator for some solid malignancies, including prostate cancer. In the present study, we evaluated the role of NLR in men who underwent prostate needle biopsy for their initial diagnosis of prostatic carcinoma. Both complete blood counts and free/total (F/T) prostate-specific antigen (PSA) ratio were examined in a total of 3,011 men in our institution. Of these, 1,207 had a PSA level between 4 and 10 ng/mL, and 357 of 810 who subsequently underwent prostate needle biopsy were found to have prostatic adenocarcinoma. NLR value was significantly higher in men with PSA of ≥ 20 ng/mL than in those with PSA of <20 ng/mL (p <0.001). NLR was also significantly higher in men with positive biopsy than in those with negative biopsy (p <0.001). Using NLR cut-off point of 2.40 determined by the AUROC curve, positive/negative predictive values of NLR alone and NLR combined with F/T PSA ratio (cut-off: 0.15) were 56.6%/60.8% and 80.7%/60.1%, respectively. Multivariate analysis revealed that not only F/T PSA ratio (HR = 3.13) but also NLR (HR = 2.21) was an independent risk factor for prostate cancer. NLR is thus likely elevated in patients with prostate cancer. Accordingly, NLR, with or without combination with F/T PSA ratio, may function as a new biomarker to predict prostate cancer in men undergoing prostate needle biopsy.

Original languageEnglish (US)
Pages (from-to)32169-32176
Number of pages8
JournalOncotarget
Volume6
Issue number31
DOIs
StatePublished - 2015

Fingerprint

Needle Biopsy
Neutrophils
Prostate-Specific Antigen
Lymphocytes
Carcinoma
Prostatic Neoplasms
Prostate
Biopsy
Blood Cell Count
Adenocarcinoma
Multivariate Analysis
Biomarkers

Keywords

  • Biomarker
  • Clinical Section
  • Neutrophil-to-lymphocyte ratio
  • Prostate cancer
  • Prostate needle biopsy

ASJC Scopus subject areas

  • Oncology

Cite this

Kawahara, T., Fukui, S., Sakamaki, K., Ito, Y., Ito, H., Kobayashi, N., ... Uemura, H. (2015). Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget, 6(31), 32169-32176. https://doi.org/10.18632/oncotarget.5081

Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. / Kawahara, Takashi; Fukui, Sachi; Sakamaki, Kentaro; Ito, Yusuke; Ito, Hiroki; Kobayashi, Naohito; Izumi, Koji; Yokomizo, Yumiko; Miyoshi, Yasuhide; Makiyama, Kazuhide; Nakaigawa, Noboru; Yamanaka, Takeharu; Yao, Masahiro; Miyamoto, Hiroshi; Uemura, Hiroji.

In: Oncotarget, Vol. 6, No. 31, 2015, p. 32169-32176.

Research output: Contribution to journalArticle

Kawahara, T, Fukui, S, Sakamaki, K, Ito, Y, Ito, H, Kobayashi, N, Izumi, K, Yokomizo, Y, Miyoshi, Y, Makiyama, K, Nakaigawa, N, Yamanaka, T, Yao, M, Miyamoto, H & Uemura, H 2015, 'Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy', Oncotarget, vol. 6, no. 31, pp. 32169-32176. https://doi.org/10.18632/oncotarget.5081
Kawahara T, Fukui S, Sakamaki K, Ito Y, Ito H, Kobayashi N et al. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget. 2015;6(31):32169-32176. https://doi.org/10.18632/oncotarget.5081
Kawahara, Takashi ; Fukui, Sachi ; Sakamaki, Kentaro ; Ito, Yusuke ; Ito, Hiroki ; Kobayashi, Naohito ; Izumi, Koji ; Yokomizo, Yumiko ; Miyoshi, Yasuhide ; Makiyama, Kazuhide ; Nakaigawa, Noboru ; Yamanaka, Takeharu ; Yao, Masahiro ; Miyamoto, Hiroshi ; Uemura, Hiroji. / Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. In: Oncotarget. 2015 ; Vol. 6, No. 31. pp. 32169-32176.
@article{62ab99b4d3a44082a1497f76cef2cb97,
title = "Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy",
abstract = "Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has been demonstrated as an independent prognosticator for some solid malignancies, including prostate cancer. In the present study, we evaluated the role of NLR in men who underwent prostate needle biopsy for their initial diagnosis of prostatic carcinoma. Both complete blood counts and free/total (F/T) prostate-specific antigen (PSA) ratio were examined in a total of 3,011 men in our institution. Of these, 1,207 had a PSA level between 4 and 10 ng/mL, and 357 of 810 who subsequently underwent prostate needle biopsy were found to have prostatic adenocarcinoma. NLR value was significantly higher in men with PSA of ≥ 20 ng/mL than in those with PSA of <20 ng/mL (p <0.001). NLR was also significantly higher in men with positive biopsy than in those with negative biopsy (p <0.001). Using NLR cut-off point of 2.40 determined by the AUROC curve, positive/negative predictive values of NLR alone and NLR combined with F/T PSA ratio (cut-off: 0.15) were 56.6{\%}/60.8{\%} and 80.7{\%}/60.1{\%}, respectively. Multivariate analysis revealed that not only F/T PSA ratio (HR = 3.13) but also NLR (HR = 2.21) was an independent risk factor for prostate cancer. NLR is thus likely elevated in patients with prostate cancer. Accordingly, NLR, with or without combination with F/T PSA ratio, may function as a new biomarker to predict prostate cancer in men undergoing prostate needle biopsy.",
keywords = "Biomarker, Clinical Section, Neutrophil-to-lymphocyte ratio, Prostate cancer, Prostate needle biopsy",
author = "Takashi Kawahara and Sachi Fukui and Kentaro Sakamaki and Yusuke Ito and Hiroki Ito and Naohito Kobayashi and Koji Izumi and Yumiko Yokomizo and Yasuhide Miyoshi and Kazuhide Makiyama and Noboru Nakaigawa and Takeharu Yamanaka and Masahiro Yao and Hiroshi Miyamoto and Hiroji Uemura",
year = "2015",
doi = "10.18632/oncotarget.5081",
language = "English (US)",
volume = "6",
pages = "32169--32176",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "31",

}

TY - JOUR

T1 - Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy

AU - Kawahara, Takashi

AU - Fukui, Sachi

AU - Sakamaki, Kentaro

AU - Ito, Yusuke

AU - Ito, Hiroki

AU - Kobayashi, Naohito

AU - Izumi, Koji

AU - Yokomizo, Yumiko

AU - Miyoshi, Yasuhide

AU - Makiyama, Kazuhide

AU - Nakaigawa, Noboru

AU - Yamanaka, Takeharu

AU - Yao, Masahiro

AU - Miyamoto, Hiroshi

AU - Uemura, Hiroji

PY - 2015

Y1 - 2015

N2 - Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has been demonstrated as an independent prognosticator for some solid malignancies, including prostate cancer. In the present study, we evaluated the role of NLR in men who underwent prostate needle biopsy for their initial diagnosis of prostatic carcinoma. Both complete blood counts and free/total (F/T) prostate-specific antigen (PSA) ratio were examined in a total of 3,011 men in our institution. Of these, 1,207 had a PSA level between 4 and 10 ng/mL, and 357 of 810 who subsequently underwent prostate needle biopsy were found to have prostatic adenocarcinoma. NLR value was significantly higher in men with PSA of ≥ 20 ng/mL than in those with PSA of <20 ng/mL (p <0.001). NLR was also significantly higher in men with positive biopsy than in those with negative biopsy (p <0.001). Using NLR cut-off point of 2.40 determined by the AUROC curve, positive/negative predictive values of NLR alone and NLR combined with F/T PSA ratio (cut-off: 0.15) were 56.6%/60.8% and 80.7%/60.1%, respectively. Multivariate analysis revealed that not only F/T PSA ratio (HR = 3.13) but also NLR (HR = 2.21) was an independent risk factor for prostate cancer. NLR is thus likely elevated in patients with prostate cancer. Accordingly, NLR, with or without combination with F/T PSA ratio, may function as a new biomarker to predict prostate cancer in men undergoing prostate needle biopsy.

AB - Neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammatory response, has been demonstrated as an independent prognosticator for some solid malignancies, including prostate cancer. In the present study, we evaluated the role of NLR in men who underwent prostate needle biopsy for their initial diagnosis of prostatic carcinoma. Both complete blood counts and free/total (F/T) prostate-specific antigen (PSA) ratio were examined in a total of 3,011 men in our institution. Of these, 1,207 had a PSA level between 4 and 10 ng/mL, and 357 of 810 who subsequently underwent prostate needle biopsy were found to have prostatic adenocarcinoma. NLR value was significantly higher in men with PSA of ≥ 20 ng/mL than in those with PSA of <20 ng/mL (p <0.001). NLR was also significantly higher in men with positive biopsy than in those with negative biopsy (p <0.001). Using NLR cut-off point of 2.40 determined by the AUROC curve, positive/negative predictive values of NLR alone and NLR combined with F/T PSA ratio (cut-off: 0.15) were 56.6%/60.8% and 80.7%/60.1%, respectively. Multivariate analysis revealed that not only F/T PSA ratio (HR = 3.13) but also NLR (HR = 2.21) was an independent risk factor for prostate cancer. NLR is thus likely elevated in patients with prostate cancer. Accordingly, NLR, with or without combination with F/T PSA ratio, may function as a new biomarker to predict prostate cancer in men undergoing prostate needle biopsy.

KW - Biomarker

KW - Clinical Section

KW - Neutrophil-to-lymphocyte ratio

KW - Prostate cancer

KW - Prostate needle biopsy

UR - http://www.scopus.com/inward/record.url?scp=84945584132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945584132&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5081

DO - 10.18632/oncotarget.5081

M3 - Article

C2 - 26359354

AN - SCOPUS:84945584132

VL - 6

SP - 32169

EP - 32176

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 31

ER -